FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) Files An 8-K Results of Operations and Financial Condition

FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

Story continues below

On April 18, 2018, Fibrocell Science, Inc. (the “Company”) disclosed in a press release preliminary financial data of cash and cash equivalents of approximately $12.2 million, as of March 31, 2018. The preliminary financial data included in the press release and this Current Report on Form 8-K have been prepared by, and are the responsibility of, the Company’s management. The Company’s independent registered public accounting firm, PricewaterhouseCoopers LLP, has not audited, reviewed, compiled or performed any procedures with respect to the preliminary financial data. Accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto.

Item 8.01 Other Events.

On April 18, 2018, the Company issued a press release announcing that its Board of Directors is conducting a comprehensive review of strategic alternatives focused on maximizing shareholder value. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.


Exhibit No.


Press Release dated April 18, 2018.

Fibrocell Science, Inc. Exhibit
EX-99.1 2 a041718finalfcscreleasev.htm EXHIBIT 99.1 a041718finalfcscreleasev Fibrocell Announces Review of Strategic Alternatives EXTON,…
To view the full exhibit click here


Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.

An ad to help with our costs